Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Shares Lead Modest Gain for BCW Index

Shares of Cepheid rose 7.4 percent for the five-day trading period ended Tuesday. The firm’s stock closed up nearly 6 percent for Tuesday alone following a presentation by CEO John Bishop at the Piper Jaffray Health Care Conference in New York (see related article, this issue). 
 
On Wednesday morning, following the close of this week’s tracking period, Piper Jaffray upgraded Cepheid’s stock to “Buy” from “Neutral.”
 
Bruker BioSciences led decliners in the Index for the week, falling 3.6 percent. Becton Dickinson was next with a drop of 3 percent for the tracking period.
 
Overall, the Index rose .1 percent. In comparison, the Dow Jones Industrial Average fell .4 percent, the Nasdaq declined .6 percent, and the Nasdaq Biotech Index slipped .1 percent.

 
BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Current Price
(November 27, 2007)
Last
Price
(November 20, 2007)
% change
Affymetrix
AFFX
20.39 20.62
-1.12
Agilent
A
36.83 36.51
0.88
Applied Biosystems
ABI
33.82 33.54
0.83
Beckman
BEC
69.35 70.36
-1.44
Becton Dickinson
BDX
81.80 84.33
-3.00
Bio-Rad
BIO
99.95 102.00
-2.01
Bruker
BRKR
8.79 9.12
-3.62
Caliper
CALP
5.31 5.32
-0.19
Cepheid
CPHD
21.98 20.47
7.38
Illumina
ILMN
52.18 51.25
1.81
Invitrogen
IVGN
94.65 91.81
3.09
Luminex
LMNX
15.27 15.10
1.13
MDS
MDZ
20.04 20.39
-1.72
Millipore
MIL
80.88 81.16
-0.34
PerkinElmer
PKI
26.87 26.76
0.41
Qiagen
QGEN
20.50 20.31
0.94
Sequenom
SQNM
8.86 8.83
0.34
Sigma-Aldrich
SIAL
51.57 50.82
1.48
Thermo
TMO
57.26 57.48
-0.38
Third Wave
TWTI
8.00 8.00
0.00
Waters
WAT
77.54 76.79
0.98
BCW Index Average 42.47 42.43
-0.1
The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.